UF researchers test stem cell therapy for heart patientsOctober 05, 2007
UF researchers plan to test the experimental therapy in people with severe coronary artery disease and daily chest pain who have not responded to traditional medications or surgical procedures designed to restore blood flow, such as angioplasty or bypass surgery.
"The general idea is that by providing these cells of blood vessel origin, we hope to either generate new blood vessels from the growth of these implanted cells or stimulate the heart to regenerate new blood vessels from the cells that reside in it," said study investigator Carl J. Pepine, M.D., chief of cardiovascular medicine at UF's College of Medicine. "It's not completely clear whether it's the actual cell itself that would do this or whether it's just the milieu and the chemical signals that occur from the cells that would result in this."
Each year, nearly half a million Americans with heart disease experience severe chest pain because coronary arteries and the smaller vessels that supply oxygen-rich blood to the heart muscle become narrowed or blocked by plaque deposits or clots. These blockages can trigger mini-heart attacks that, while too small to be noticed as they occur, over time irreversibly damage the heart - leading to disability, progressive heart failure or even death.
In the prospective, double-blind, placebo-controlled study, known as the Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia Trial, or ACT34-CMI, UF researchers will study 15 Shands at UF medical center patients to determine whether a person's own stem cells can be used to effectively and safely treat chronic reductions in blood flow to the heart, improving symptoms and long-term outcomes. They also will evaluate whether participants report improved quality of life and exercise tolerance, and whether the heart functions better.
Participants will undergo screening tests and then receive a series of injections of a protein that releases stem cells from the bone marrow into the bloodstream. The cells, known as CD34+ stem cells, help spur blood vessel growth and are harvested from the patient during a procedure called apheresis, said Chris Cogle, an assistant professor of medicine at the UF's College of Medicine Program in Stem Cell Biology and Regenerative Medicine.
Participants will then be randomly assigned to receive one of two dosing levels of the cells, or a placebo.
"Physicians will use a catheter-based electrical mapping system to find muscle they think is still viable but not functioning," said R. David Anderson, an associate professor of medicine at UF and director of interventional cardiology. "The cells are injected into viable sites in the heart, which have poor blood flow, in the cardiac catheterization laboratory at Shands at UF medical center."
Patients will be periodically evaluated by echocardiography and magnetic resonance imaging over the course of a year after the procedure. Although to date study subjects have tolerated this procedure well, potential risks include infection, allergic reactions, bleeding, blood clots and damage to the heart or its vessels.
UF is one of 20 research sites participating in the national study, which is evaluating a total of 150 patients and is sponsored by the Cellular Therapies business unit of Baxter Healthcare Corp. and led by principal investigator Douglas Losordo, M.D., of Northwestern University's Feinberg School of Medicine. Baxter makes the cell-sorting equipment used to isolate the cells from the blood.
Pending Food and Drug Administration approval, UF researchers, through the National Heart, Lung and Blood Institute-funded Cardiovascular Cell Therapy Research Network, are gearing up to launch three other multicenter studies within the next several months that use other types of a patient's own stem cells.
One trial focuses on patients who have had a heart attack within a week preceding study enrollment, another focuses on patients whose heart attack occurred within the preceding two to three weeks, and the third focuses on patients with congestive heart failure or chronic chest pain that has not responded to traditional treatment.
These studies will use stem cells taken directly from the patients' bone marrow instead of stem cells isolated from the bloodstream, Pepine said, and will test whether various cell therapies can improve the heart's plumbing by helping to repair blood vessels or form new ones and strengthen the heart muscle to improve its ability to pump efficiently.
Douglas E. Vaughan, M.D., chief of the division of cardiovascular medicine at Vanderbilt University Medical Center, said the study is important and targets a challenging group of patients who need new options.
"There's a lot of enthusiasm in the cardiovascular community about the potential of cell-based therapies for the treatment of cardiovascular diseases," Vaughan said, "and there is increasing experience around the world in using bone marrow-derived stem cells in patients with cardiovascular disease. There is growing confidence this is going to be a safe form of therapy, but there are continuing questions about how effective it will be and what its impact will be in individual patients."
University of Florida
Related Stem Cells Current Events and Stem Cells News Articles
Key to aging immune system is discovered
There's a good reason people over 60 are not donor candidates for bone marrow transplantation. The immune system ages and weakens with time, making the elderly prone to life-threatening infection and other maladies, and a UC San Francisco research team now has discovered a reason why.
Senescence in adipose-derived stem cells and its implications in nerve regeneration
Adult mesenchymal stem cells, specifically adipose-derived stem cells have self-renewal and multiple differentiation potentials and have shown to be the ideal candidate for therapeutic applications in regenerative medicine, particularly in peripheral nerve regeneration.
Transplantation shown to be highly effective in treating immune deficiency in children
Babies who are born with severe combined immunodeficiency (SCID) can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering's Richard J. O'Reilly, MD, a world-renowned pioneer in the development of transplant protocols.
Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery
Advertising claims for cosmetic procedures using stem cells are running far ahead of the scientific evidence for safety and effectiveness, according to a review in the August issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
Sugar mimics guide stem cells toward neural fate
Embryonic stem cells can develop into a multitude of cells types. Researchers would like to understand how to channel that development into the specific types of mature cells that make up the organs and other structures of living organisms.
Stem cell advance may increase efficiency of tissue regeneration
A new stem-cell discovery might one day lead to a more streamlined process for obtaining stem cells, which in turn could be used in the development of replacement tissue for failing body parts, according to UC San Francisco scientists who reported the findings in the current edition of Cell.
How does microRNA-124 promote the neuronal differentiation of BMSCs?
MicroRNAs (miRNAs) play an important regulatory role in the self-renewal and differentiation of stem cells. Dr. Defeng Zou and co-workers from the First Affiliated Hospital of China Medical University, China focuses on the effect of miRNA overexpression on the differentiation of bone marrow-derived mesenchymal stem cells into neurons.
NYSCF scientists one step closer to cell therapy for multiple sclerosis patients
Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient's own cells.
Researchers in Germany and the U.S. have proven for the first time that specific individual cells of the immune system, termed central memory T cells, have all the essential characteristics of adult tissue stem cells. Such cells are capable of perpetuating themselves indefinitely as well as generating diverse offspring that can reconstitute "tissue" function.
Marmoset sequence sheds new light on primate biology and evolution
An international team of scientists led by the Baylor College of Medicine and Washington University St. Louis, including a researcher from the University of Veterinary Medicine, Vienna have completed the genome sequence of the common marmoset - the first sequence of a New World Monkey - providing new information about the marmoset's unique rapid reproductive system, physiology and growth shedding new light on primate biology and evolution.
More Stem Cells Current Events and Stem Cells News Articles